Serving up whatever you wish: CRISPR-base editing generates novel cancer-restricted antigens for immunotherapy.

Autor: Burkhardt UE; Accelerating Cancer Immunotherapy Research, Concord, MA, USA. ute.burkhardt@acir.org., Fritsch EF; Accelerating Cancer Immunotherapy Research, Concord, MA, USA. ed.fritsch@acir.org.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ed.fritsch@acir.org.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. ed.fritsch@acir.org.

Publikováno v: Genes and immunity [Genes Immun] 2023 Dec; Vol. 24 (6), pp. 292-294. Date of Electronic Publication: 2023 Dec 11.

A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens.

Autor: Hu Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Anandappa AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Sun J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Kim J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Leet DE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Bozym DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Chen C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Williams L; Broad Institute of MIT and Harvard, Cambridge, MA., Shukla SA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Zhang W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Tabbaa D; Broad Institute of MIT and Harvard, Cambridge, MA., Steelman S; Broad Institute of MIT and Harvard, Cambridge, MA., Olive O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Livak KJ; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Kishi H; Department of Immunology, University of Toyama, Toyama, Japan., Muraguchi A; Department of Immunology, University of Toyama, Toyama, Japan., Guleria I; Department of Pathology, Brigham and Women's Hospital, Boston, MA., Stevens J; Department of Pathology, Brigham and Women's Hospital, Boston, MA., Lane WJ; Harvard Medical School, Boston, MA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA., Burkhardt UE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Fritsch EF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Neuberg D; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA., Ott PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA; and., Keskin DB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA; and., Hacohen N; Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; Massachusetts General Hospital, Boston, MA., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA; and.

Publikováno v: Blood [Blood] 2018 Nov 01; Vol. 132 (18), pp. 1911-1921. Date of Electronic Publication: 2018 Aug 27.

Toward the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14-16, 2013.

Autor: Kloke BP; Ribological GmbH, Hölderlinstraße 8, 55131, Mainz, Germany, bjoern.kloke@ribological.de., Rae R, Mahr A, Burkhardt UE, Kvistborg P, Britten CM

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2014 Jul; Vol. 63 (7), pp. 749-55. Date of Electronic Publication: 2013 Nov 05.

Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.

Autor: Burkhardt UE; Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA., Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Sievers QL, Brusic A, McDonough SM, Zeng W, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP, Wu CJ

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2013 Sep; Vol. 123 (9), pp. 3756-65. Date of Electronic Publication: 2013 Aug 05.

IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells.

Autor: Burkhardt UE; Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Paul-Ehrlich-Straße 42-44, 60596 Frankfurt am Main, Germany., Sloots A, Jakobi V, Wei WZ, Cavallo F, Kloke BP, Wels WS

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2012 Sep; Vol. 61 (9), pp. 1473-84. Date of Electronic Publication: 2012 Feb 14.